PlasmIT is building PiMed to serve an estimated US$6 billion market spanning approximately 9,000 hospitals, 110,000 ICU beds and 2.5 million general beds.
At scale, this represents the potential to support care delivery for approximately 6 million ICU patients and 400 million general-bed patients.
PiMed has reached MVP stage and is being prepared for commercial pilots. Leading hospitals in India have reviewed the solution, and PlasmIT has signed memoranda of understanding with hospital partners in India while building relationships in selected international markets.
Our ambition is to help critical-care teams act on timely clinical information and contribute to better outcomes for millions of people.
Market size, infrastructure and patient-reach figures are internal management estimates. Commercial-readiness and partnership statements are based on supplied investor materials. All statements are forward-looking and subject to investor verification.